Access cutting-edge mucosal melanoma treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access mucosal melanoma specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related mucosal melanoma treatment provided free
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. T
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this mucosal melanoma clinical trial in Palo Alto, CA
If you're searching for mucosal melanoma treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mucosal melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.